The Pharmacogenetics of Asthma Treatment (PhAT) project seeks to investigate
genetic determinants of the variation in the treatment response to asthma. PharmGAT
is funded as part of the National Institute of General Medical Sciences (NIGMS) and
National Heart, Lung, and Blood Institutes (NHLBI) Pharmacogenetics Research Network
and Knowledge Base (PGRN); the national repository for pharmacogenetics information
generated by this network is known as the Pharmacogenetics and Pharmacogenomics
Knowledge Base (PharmGKB). PharmGAT consists of investigators from the Brigham
and Womens Hospital, the University of Cincinnati, and the University of Colorado.
The long term objective of PharmGAT includes the ability to individualize therapy
prospectively for subjects identified with asthma, allowing for optimal therapeutic
effect while minimizing side effects. Additionally, since the pathophysiologic and
therapeutic pathways of asthma overlap with many other diseases, the findings generated
by this program may have much broad implications.